NRXS Form 4: Director Bradley Watkins receives 13,157 shares

Rhea-AI Filing Summary

Neuraxis, Inc. (NRXS) reported an insider equity grant to director Bradley M. Watkins. On 01/17/2025 Mr. Watkins was issued 13,157 shares of common stock as compensation for his services as an independent director at an effective price of $2.85 per share. After the issuance he beneficially owned 24,737 shares in a direct ownership form. The Form 4 was signed by Mr. Watkins on 09/10/2025. This filing records a routine director compensation equity award and does not include derivative transactions.

Insights

Financial Analyst

TL;DR: Routine director stock issuance; minor ownership change, no derivatives disclosed.

The Form 4 documents a standard equity compensation payment: 13,157 common shares issued to a director at $2.85 per share, resulting in 24,737 shares directly owned. For investors this is a small, non-cash compensation event that slightly increases outstanding shares and aligns a board member with shareholder interests. There is no indication of stock sales, option exercises, or other transactions that would materially affect liquidity or capital structure. The filing is informational and typical for governance-related compensation.

Corporate Governance Expert

TL;DR: Governance routine—director received equity for services; disclosure meets Section 16 requirements.

The report shows compliance with Section 16 reporting: issuance date, amount, price, and post-transaction ownership are disclosed. Issuance as director compensation is a common governance practice to align incentives. The direct ownership amount is provided and no indirect holdings or related derivative positions are reported, which simplifies beneficial ownership analysis. The signature date appears later than the transaction date, consistent with a timely filed Form 4 if within permissible reporting windows.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Watkins Bradley Mitchell

(Last) (First) (Middle)

11611 N. MERIDIAN ST, SUITE 330

(Street)

CARMEL IN 46032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/17/2025		A		13,157	A	$2.85(1)	24,737	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

	/s/ Bradley M. Watkins	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Bradley M. Watkins report on Form 4 for NRXS?

The Form 4 reports that Bradley M. Watkins was issued 13,157 shares of Neuraxis common stock on 01/17/2025 as compensation for his services as an independent director.

At what price were the shares issued to the director on NRXS Form 4?

The shares were recorded at an effective price of $2.85 per share.

How many Neuraxis (NRXS) shares does Bradley M. Watkins beneficially own after the transaction?

Following the issuance, Mr. Watkins beneficially owned 24,737 shares in a direct ownership form.

Does the Form 4 for NRXS disclose any derivative transactions for Bradley M. Watkins?

No. The filing shows only a non-derivative issuance of common stock and does not disclose any derivative securities transactions.

When was the Form 4 signed by the reporting person?

The signature on the Form 4 is dated 09/10/2025.